Cancer Immunotherapy: Top 10 Things Patients Need to Know with Sunshine Pegues & Dr. Laurie Glimcher

President and CEO of the Dana-Farber Cancer Institute, Laurie H. Glimcher, M.D., along with cancer survivor and CRI ImmunoAdvocate Sunshine Pegues, discuss the top ten things patients need to know about #immunotherapy. #CRIwebinar https://www.cancerresearch.org/webinars In this webinar for patients and caregivers, Dr. Glimcher and Sunshine share the latest perspectives from the research frontlines and the immunotherapy patient experience. Who can be treated with immunotherapy? What factors affect cancer development and immunotherapy responses? Where can patients find immunotherapy clinical trials? How are vaccines used against cancer? What are the potential side effects of immunotherapy? What is genomic screening and should patients ask for it? And more of these topics are covered in this webinar. Laurie H. Glimcher, M.D., a longtime member of the Cancer Research Institute Scientific Advisory Council, is the president and CEO of the Dana-Farber Cancer Institute, as well as the director of the Dana-Farber/Harvard Cancer Center and the Richard and Susan Smith Professor of Medicine at Harvard Medical School. During her career as a distinguished immunologist that has seen her publish more than 350 papers, Dr. Glimcher has been inducted into many prestigious organizations, including the National Academy of Sciences, the National Academy of Medicine, and the American Academy of Arts and Sciences. She has also received numerous awards, including the American Association of Immunologists Lifetime Achievement Award and the L'Oréal-UNESCO Award for Women in Science, and CRI’s William B. Coley Award. In 2011, Sunshine Pegues was diagnosed with stage 4 non-small cell lung cancer. Standard treatment at the time was chemotherapy followed by 35 days of radiation, which burned the skin on her neck and left her in more pain and skeptical about the advice of her health care team. She moved back to her hometown, Seattle, where she enrolled in two clinical trials. The second trial tested nivolumab (Opdivo), an anti-PD-1 immunotherapy, which stopped her cancer from progressing and eventually, caused it to become inactive. The Cancer Immunotherapy and You™ webinar series is produced by the Cancer Research Institute and is hosted by our assistant director of scientific content, Arthur N. Brodsky, Ph.D. The 2022 series is made possible with generous support from Bristol Myers Squibb with additional support from Alkermes, BioCanRx, and Lilly Oncology. Browse our Cancer Immunotherapy and You Webinars playlist on YouTube or visit the Webinars page on our website to see other webinars in this series. https://www.cancerresearch.org/webinars Established in 1953, the Cancer Research Institute (CRI) is a 501(c)(3) nonprofit organization dedicated to harnessing our immune system’s power to control and potentially cure all cancers. Our mission: Save more lives by fueling the discovery and development of powerful immunotherapies for all types of cancer. To accomplish this, we rely on donor support and collaborative partnerships to fund and carry out the most innovative clinical and laboratory research around the world, support the next generation of the field’s leaders, and serve as the trusted source of information on immunotherapy for cancer patients and their caregivers. https://www.cancerresearch.org Cancer Research Institute is a registered 501(c)(3) nonprofit under EIN 13-1837442. Donations are tax-deductible to the fullest extent allowable under the law.